Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

XBIT

XBiotech (XBIT)

XBiotech Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:XBIT
일자시간출처헤드라인심볼기업
2025/03/2004:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XBITXBiotech Inc
2025/03/1904:36Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:XBITXBiotech Inc
2025/02/0506:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XBITXBiotech Inc
2025/01/2804:36Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:XBITXBiotech Inc
2025/01/0105:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XBITXBiotech Inc
2024/12/2323:00GlobeNewswire Inc.XBiotech Pauses Rheumatology programNASDAQ:XBITXBiotech Inc
2024/11/1405:12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
2024/08/1303:38Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
2024/06/2101:57Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XBITXBiotech Inc
2024/06/1900:35GlobeNewswire Inc.XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic CancerNASDAQ:XBITXBiotech Inc
2024/05/1100:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
2024/02/0802:36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
2024/02/0802:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:XBITXBiotech Inc
2024/01/0600:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:XBITXBiotech Inc
2024/01/0423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:XBITXBiotech Inc
2024/01/0423:00GlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
2024/01/0423:00GlobeNewswire Inc.XBiotech to Begin Constructing New R&D Facility on its 48-acre CampusNASDAQ:XBITXBiotech Inc
2023/11/1423:00GlobeNewswire Inc.Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisNASDAQ:XBITXBiotech Inc
2023/11/1004:41Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
2023/09/2622:00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeNASDAQ:XBITXBiotech Inc
2023/08/3022:00GlobeNewswire Inc.XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic CancerNASDAQ:XBITXBiotech Inc
2023/08/1200:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:XBITXBiotech Inc
2023/08/0900:47GlobeNewswire Inc.XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialNASDAQ:XBITXBiotech Inc
2023/06/2621:48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
2023/06/2621:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
2023/06/2621:43Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
2023/06/2621:40Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:XBITXBiotech Inc
2023/06/2404:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:XBITXBiotech Inc
2023/06/2022:20Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:XBITXBiotech Inc
2023/05/2222:00GlobeNewswire Inc.FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsNASDAQ:XBITXBiotech Inc
 검색 관련기사 보기:NASDAQ:XBIT